Sir,
Cutaneous T-cell lymphoma (CTCL) defines a group of lymphoproliferative disorders that primarily affects the skin. Mycosis fungoides (MF) is the most common clinical variant of CTCL comprising almost 50% of all patients diagnosed with primary T-cell lymphoma. 1 The etiology and pathogenesis of the disease remain poorly understood. Recent data suggest that environmental factors such as bacteria rather than heredity play an important role in the pathogenesis and disease progression. [2] [3] [4] Although angiogenesis generally plays a key role in tumor growth and metastasis and is considered one of the hallmarks of cancer, 5 little is known about angiogenesis in CTCL. However, recent data demonstrated that micro-vessel formation and the density of micro-vessels in CTCL skin lesions correlate with disease progression suggesting that angiogenesis plays a role in the pathogenesis. 6 Notably, malignant inflammation defined as a pro-tumorigenic inflammatory environment orchestrated by the tumor cells plays a key role in disease progression (reviewed in ref. 7) . Accordingly, we hypothesized that malignant T cells also orchestra angiogenesis in affected skin. In support, malignant T cells spontaneously produce angiogenic factors such as VEGF-A, VEGF-C and lymphotoxin-alpha [8] [9] [10] [11] and induce increased vascularization and production of angiogenic factors in vivo.
12
Recent observations indicate that IL-17 family cytokines stimulate and modulate oncogenic angiogenesis. 13 Interestingly, due to abnormal activation of the JAK3/STAT3 signaling pathway, malignant T cells spontaneously express IL-17F and a fraction of MF patients display increased levels of IL-17A and/or IL-17F in lesional skin at levels comparable to those found in skin lesions from patients with psoriasis, 14 a disease which is also associated with increased angiogenesis. 15 Since malignant MF T cells constitutively express IL-17F and the expression in lesional skin is associated with progressive disease, 14 we hypothesized that malignant T cells partly promote angiogenesis through the expression of IL-17F in MF patients. Accordingly, we plated endothelial cells (HUVEC) on growth factor depleted matrigel in vitro with or without culture supernatant from malignant T cell lines (MyLa2059 and PB2B cells both of which spontaneously produce IL-17F 14 ) to assay for IL-17F mediated induction of endothelial sprouting and tube formation as described elsewhere. 14 The effect of Figure S3) . We have previously shown that STAT3 signaling pathway drives malignant IL-17F expression. 14 Together, our finding indicates that therapeutic inhibition of classic angiogenic pathways, like VEGF, will not affect IL-17F production by malignant T cells. As mentioned above, the malignant T cells in question did not produce IL-17A, but it is seems likely that IL-17A producing malignant T cells may also contribute to the induction of angiogenesis in CTCL patients. Interestingly, simultaneous expression of IL-17A and IL-17F by malignant T cells leads to IL-17A/IL-17F heterodimer formation in malignant supernatant 14 and as shown in Figure 2b (column 6) IL-17A and IL-17F induce an enhanced response when compared to either cytokine alone. Some patients with CTCL display high levels of IL-17A, others display high levels of IL-17F, while some display high levels of both cytokines in their lesional skin. 14 The average expression of IL-17A and IL-17F was increased in advanced stages of CTCL when compared to early stages, indicating that both IL-17 family cytokines may be involved in disease progression although only the correlation between IL-17F and progressive disease was statistically significant.
14 Thus, it is conceivable that it is the total level of IL-17A/IL-17F (alone or in combination) that determines the impetus of these cytokines on the angiogenesis in MF. Taken together, the present findings suggest that malignant T cells orchestra angiogenesis and malignant inflammation in tandem, which might play an important role during the accelerating disease progression observed in advanced stages of the disease.
In conclusion, the present study provides the first evidence that malignant T cells stimulate angiogenesis through release of IL-17F suggesting that IL-17F might serve as a novel target for antiangiogenic therapy. 
